Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes
Lung cancer patients who take medications called GLP-1 receptor agonists — commonly prescribed for weight loss and diabetes management — fare better than those who don’t, according to research.
Clinical Scorecard: Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes
At a Glance
Category Detail
Condition Non-Small Cell Lung Cancer (NSCLC) Key Mechanisms GLP-1 receptor agonists (GLP-1RAs) enhance anti-tumor immunity and improve tumor microenvironment. Target Population Overweight or obese patients with NSCLC. Care Setting Oncology and surgical settings.
Key Highlights
GLP-1RAs improve recurrence-free survival in post-surgical NSCLC patients. Concurrent use of GLP-1RAs with immune checkpoint inhibitors enhances overall and progression-free survival. Benefits of GLP-1RAs are primarily observed in overweight or obese patients. GLP-1RAs are FDA-approved for weight loss and diabetes management. Research indicates a potential role in enhancing immunotherapy effectiveness. Guideline-Based Recommendations
Diagnosis
Consider GLP-1RA use in overweight or obese NSCLC patients. Management
Incorporate GLP-1RAs in treatment plans for eligible NSCLC patients to improve outcomes. Monitoring & Follow-up
Monitor recurrence-free survival and overall survival in patients using GLP-1RAs. Risks
Further research needed to understand long-term effects and risks associated with GLP-1RA use in cancer patients. Patient & Prescribing Data
Patients with non-small cell lung cancer, particularly those who are overweight or obese.
GLP-1RAs may enhance the efficacy of existing cancer therapies, particularly immunotherapy.
Clinical Best Practices
Evaluate the potential benefits of GLP-1RAs in the context of NSCLC treatment. Engage in multidisciplinary discussions regarding the integration of GLP-1RAs in treatment protocols. References
